Welcome to the Irish Food Allergy Network


This site is intended as a guide to assist those who, through their work, encounter children and families affected by food allergy.

The site content is intended for use by regulated healthcare professionals.  Its aim is to help in diagnosing and managing suspected food allergy by regulated health care staff in community and hospital settings.  Reproduction of content or referencing IFAN outside of this context requires advance permission, please contact us.

We welcome your feedback and comments.  This site is a work in progress, it will be modified according to feedback received by you-its users.

Privacy and Cookie policy

At IFAN, we have tried to be as transparent as possible about your privacy and use of cookies.  Access our policy in full here

Statement of disclosure

IFAN acknowledges that finance in the form of unrestricted educational support is required in order for its educational and professional aims and objectives to be achieved.

IFAN is grateful for the generous support that has been provided to date by members of industry and pharma as listed here in the contributors’ section, whose disclosure statements are published alongside.

IFAN is committed to best practice with regard to interactions with industry and pharma to ensure that committee member’s professional independence of judgement is not affected by receipt of financial support.

All financial support received by IFAN from industry & pharma is lodged to and managed by IFAN’s unrestricted Education and Development Funds without influence.

Committee members have attended educational meetings funded by commercial enterprises and have received speakers fees. They have/have had complete control over lecture content which is based on evidence based information independent of influence.

IFAN declares that its officers’ and members’ independence of judgement is the basis of its advocacy and educational roles and is not influenced by the financial support received. Any views expressed in IFAN’s literature, website or presentations are sincerely held. If any person identifies any conflict or ambiguity IFAN will address the issue immediately, and will publish any clarifications or alterations required.

December 2018.


Recent News & Articles


Peanut immunotherapy trial results: desensitisation in peanut allergic children

A trial of oral immunotherapy in children and adolescents highly allergic to peanut, treated with AR101 resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms according to research published yesterday. To see

Advisory notice: Emerade Adrenaline Autoinjector devices.

The Health Products Regulatory Authority (HPRA) wishes to inform users and healthcare professionals of the following potential quality defect for the Emerade range of treatments There is a possibility that a small percentage (0.015%) of Emerade pens

Twitter Feed

IFANdotIE @IFANdotIE
IFAN  @IFANdotIE
RT @BDA_FASG:NEW guidance for healthcare professionals on prevention of food allergy in high risk infants- collaboration between… https://t.co/bXnxG8BFEf 
IFAN  @IFANdotIE
RT @EAACI_HQ:The death of Professor Anthony J. Frew causes deepest sorrow within EAACI Family. Professor Frew was a fantastic sc… https://t.co/54fC9Lv28w 

 
IFAN's publications are endorsed by the Irish Association of Allergy and Immunology and the Irish Nutrition and Dietetic Institute

The information, algorithms and care pathways contained on this site represent the view of IFAN, which was arrived at after careful consideration of the extensive evidence available.

It is the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient.

Material may be freely reproduced for educational and non-profit purposes.

No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of IFAN

In order to improve our service to you please answer this quick survey.